Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
HDAC3
REST API REST API
Homo sapiens
HDAC3 is differentially expressed in 214 experiments: 102 organism parts: cerebellum, accumbens, ... (100 more);, 139 disease states: normal, glioblastoma, ... (137 more);, 68 cell types 299 cell lines 27 compound treatments and 64 other conditions.
Synonyms RPD3, RPD3-2, HD3
Orthologs hdac3 (Danio rerio)   ENSCING00000002360 (Ciona intestinalis)   F1NH59_CHICK (Gallus gallus)   RPD3 (Saccharomyces cerevisiae)   HDAC3_RAT (Rattus norvegicus)   Hdac3 (Mus musculus)   Q6RCM5_BOVIN (Bos taurus)   Hdac3 (Drosophila melanogaster)   hdac3 (Xenopus laevis)   LOC478040 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term regulation of multicellular organism growth, transcriptional repressor complex, DNA binding, negative regulation of transcription, DNA-dependent, protein binding, histone deacetylase activity, histone deacetylase complex, cytoplasm, transcription corepressor activity, spindle microtubule, anti-apoptosis, regulation of mitotic cell cycle, transcription factor binding, histone deacetylase binding, histone deacetylation, nucleus, negative regulation of JNK cascade, response to drug, chromatin binding, hydrolase activity, chromatin modification, chromatin, nucleoplasm, negative regulation of transcription from RNA polymerase II promoter, spindle assembly, negative regulation of cell cycle, circadian regulation of gene expression, protein deacetylase activity, NAD-dependent histone deacetylase activity (H3-K9 specific), nerve growth factor receptor signaling pathway, cellular lipid metabolic process, protein deacetylation, NAD-dependent histone deacetylase activity (H4-K16 specific), NAD-dependent histone deacetylase activity (H3-K14 specific), histone deacetylase activity (H3-K16 specific)
InterPro Term His_deacetylse, His_deacetylse_1, His_deacetylse_dom
UniProt Accession Q9H368, O15379, B5MGH4, E7ESJ6, E7EWI8, E7EW19
Search EB-eye ENSG00000171720
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MTAB-24, E-MTAB-25, ... (17 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-19397, E-GEOD-4717, ... (30 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529
MOLT4
2
E-MTAB-37, E-MTAB-62
T47D
2
E-MEXP-440, E-MTAB-62
C7H2-R9C10
1
E-GEOD-22152
JEKO-1
1
E-MTAB-62
rpmi-8226
1
E-MTAB-62
293 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-3920, E-GEOD-20677, E-GEOD-13909, E-GEOD-13987, ... (34 experiments)

Factor Value U/D Experiments
monocyte
2
E-GEOD-22373, E-MEXP-583
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
plasma cell
1
E-MEXP-2360
activated natural killer cell
1
E-TABM-702
endothelial cell
1
E-GEOD-3920
native fetal RPE
1
E-GEOD-18811
62 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-22148, E-MEXP-121, E-MTAB-62, ... (33 experiments)

Factor Value U/D Experiments
glioblastoma
1
3
E-GEOD-4290, E-MTAB-62, E-GEOD-4412, E-GEOD-6014
embryonal rhabdomyosarcoma
2
E-MTAB-62, E-MEXP-121
lymphoma
2
E-MTAB-62, E-MTAB-37
Aggressive, chronic myelogenous leukemia
1
E-MTAB-62
Lung small cell cancer
1
E-MTAB-62
cutaneous T cell lymphoma
1
E-MTAB-37
133 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-15205, E-TABM-782, E-GEOD-5824, E-GEOD-3720, ... (17 experiments)

Factor Value U/D Experiments
TTA
1
E-MEXP-2590
vanadium pentoxide
1
E-GEOD-5339
unknown
1
E-GEOD-7307
M-CSF
1
E-GEOD-5099
glucose
1
E-MEXP-941
glutamine
1
E-MEXP-941
21 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, E-GEOD-1725 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-21589, E-GEOD-16363

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-GEOD-4667, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-22148, E-TABM-147, E-GEOD-21138, E-GEOD-3013 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011, E-MEXP-1482, E-GEOD-7578

Genotype
studied in E-TABM-763, E-GEOD-3494, E-GEOD-17476, E-GEOD-22593, E-GEOD-2292, ... (9 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-12773, E-MEXP-1446, E-GEOD-22278, ... (8 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-GEOD-16363, ... (25 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-980

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

organ
studied in E-GEOD-24283

Organism
studied in E-AFMX-1, E-GEOD-426

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-22152, E-GEOD-21750, E-GEOD-17636

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-1703, E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-18995

Sex
studied in E-GEOD-1643, E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-TABM-276, E-GEOD-2748

Tissue
studied in E-GEOD-30573

Treatment
studied in E-GEOD-16837, E-GEOD-21909, E-GEOD-19246, E-GEOD-19815, E-GEOD-15799, ... (6 experiments)

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-4922

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.251 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM